The USFDA has amended the emergency use authorizations for the updated formulations of mRNA-1273 and BNT162b2 COVID-19 vaccines to include their use in children up to 6 months of age. Updates for parents and caregivers of children 6 months through 5 years of age Children who have received the original monovalent mRNA-1273 vaccine are now eligible for a single booster of the updated bivalent vaccine two months after completing a primary series with the monovalent vaccine.
6 months through 4 years of age Those who have not started their three-dose primary series of the BNT162b2 COVID-19 vaccine or have not received the third dose of the primary series are now eligible to receive the updated (bivalent) BNT162b2 COVID vaccine as the third dose in their primary series following two doses of the original (monovalent) vaccine. 6 months through 4 years of age Those who have completed the…
